Estrogen Protects Female Mice From FGF23-Induced Cardiac Hypertrophy

Chronic kidney disease is an independent, graded risk factor for all-cause mortality and major cardiovascular events, with the risk of death increasing significantly as the estimated glomerular filtration rate falls below 60 ml per minute per 1.73 m² [1]. Within this population, the development of left ventricular hypertrophy is a critical prognostic marker that carries an adverse prognosis and increases the risk of progression to congestive heart failure [2]. Meta-analyses indicate that patients with renal impairment face a substantially higher burden of cardiovascular mortality and sudden cardiac death compared to those with normal kidney function [3]. While clinical guidelines emphasize the importance of managing comorbidities like hypertension and diabetes to prevent heart failure, the biological basis for observed sex-specific differences in cardiac outcomes remains poorly understood [4, 5]. A recent study investigates the molecular mechanisms that may protect the female heart during the progression of renal decline, offering insights that could eventually guide sex-specific cardiovascular risk stratification in nephrology clinics.